Help Pharmacy Pricing Analysis & Total Cost

What Is Help Pharmacy?

Help Pharmacy is an FDA-registered 503B outsourcing facility headquartered in Houston, Texas. It compounds prescription medications, including GLP-1 receptor agonists, peptides, and hormone replacement therapies, under current Good Manufacturing Practices (cGMP). The pharmacy holds accreditation from the Pharmacy Compounding Accreditation Board (PCAB), a distinction held by fewer than 3% of U.S. compounding pharmacies.

503B facilities operate under Section 503B of the Federal Food, Drug, and Cosmetic Act, which allows them to compound drugs without individual patient prescriptions in advance, subject to FDA oversight and routine inspections [1]. This regulatory pathway distinguishes Help from traditional 503A compounding pharmacies, which prepare medications only after receiving a patient-specific prescription. The practical difference: 503B facilities can produce medications in larger batches with more standardized quality controls, including potency testing, sterility assurance, and endotoxin screening [2].

Help does not prescribe medications. Patients need a prescription from a licensed provider, either their own physician or a telehealth clinician through one of several partner platforms that route prescriptions to Help for fulfillment.

Compounded GLP-1 Pricing Breakdown

Compounded semaglutide from Help costs roughly $150 to $350 per month, depending on the prescribed dose and whether a patient accesses the pharmacy through a direct prescription or a telehealth partner. That range sits well below the $1,349.02 list price for a 4-week supply of brand-name Wegovy (semaglutide 2.4 mg) reported by Novo Nordisk [3].

Several factors drive this gap. Compounded versions use semaglutide base or semaglutide sodium salt, not the branded formulation. The FDA has clarified that compounding of drugs on the shortage list is permitted under 503B regulations, and semaglutide appeared on the FDA Drug Shortage Database intermittently from 2022 through early 2024 [4]. The pricing structure reflects lower raw ingredient costs, absence of brand-manufacturer margins, and the batch-production efficiencies of a 503B facility.

For tirzepatide (the active ingredient in Mounjaro and Zepbound), compounded pricing from Help generally ranges from $200 to $450 per month. Brand Zepbound carries a list price of approximately $1,059.87 per 4-week supply [5].

A key variable: dose escalation. GLP-1 protocols typically start at lower doses and titrate upward over 16 to 20 weeks. A patient on compounded semaglutide 0.25 mg pays considerably less than one stabilized at 2.4 mg. Ask your prescribing provider for a dose-specific price quote before starting.

Total Cost: Beyond the Medication Price

The sticker price of the compounded drug is only part of the bill. Total monthly cost includes the medication itself, provider or platform consultation fees, and shipping.

Telehealth platform fees vary widely. Some platforms that partner with Help charge $0 for initial consultations and bundle costs into the medication price. Others charge $49 to $99 per month for ongoing provider access, lab review, and dose adjustments. A 2023 analysis of direct-to-consumer telehealth GLP-1 platforms found that bundled monthly costs (medication plus provider fees) ranged from $199 to $599 depending on the molecule, dose tier, and platform [6].

Shipping costs range from free to approximately $15 per shipment, depending on the provider and shipping speed. Cold-chain medications like GLP-1 injectables require insulated packaging, which some platforms absorb into the medication cost.

Lab work is another consideration. The Endocrine Society's 2024 clinical practice guideline on pharmacologic management of obesity recommends baseline labs including fasting glucose, HbA1c, lipid panel, and hepatic function before initiating GLP-1 therapy [7]. Some telehealth platforms include lab orders in their subscription fee. Others require patients to obtain labs independently, adding $50 to $200 out-of-pocket if uninsured.

A realistic total monthly cost estimate for compounded semaglutide through a telehealth-plus-Help pathway: $199 to $449 all-in, depending on dose, platform, and whether labs are bundled. Compare that to brand Wegovy at $1,349 per month without insurance, or $0 to $25 per month with manufacturer savings cards for commercially insured patients [3].

Is Help Pharmacy Legitimate?

Yes. Help holds three credentials that matter for safety evaluation. First, FDA registration as a 503B outsourcing facility subjects it to periodic FDA inspections. Inspection reports are publicly available through the FDA's inspection database. Second, PCAB accreditation requires compliance with USP (United States Pharmacopeia) standards for sterile and non-sterile compounding, including USP <797> and USP <800> [8]. Third, Help reports third-party potency and sterility testing on its compounded products.

No compounding pharmacy is without risk. The FDA has issued warning letters and 483 observations to various compounding facilities over the years. The 2012 New England Compounding Center (NECC) meningitis outbreak, which killed 76 people and sickened 753, prompted the Drug Quality and Security Act of 2013 that created the 503B regulatory framework Help operates under [9]. That framework requires beyond-use dating protocols, adverse event reporting, and batch-level testing that 503A pharmacies do not face.

"The 503B pathway was designed to provide a higher level of oversight for compounding facilities that produce drugs in large quantities," noted Dr. Janet Woodcock, then-FDA Principal Deputy Commissioner, in testimony before the Senate HELP Committee [10].

Patients should verify that any compounding pharmacy they use holds current FDA registration and has no unresolved warning letters.

Help Pharmacy vs. Alternatives

The compounding pharmacy market for GLP-1 agonists has expanded rapidly. Help competes with other 503B facilities (Hallandale Pharmacy, Olympia Pharmaceuticals, Strides Pharma) and an increasing number of telehealth-integrated pharmacies.

Price comparison (approximate monthly cost, compounded semaglutide at maintenance dose):

• Help Pharmacy: $150 to $350 (medication only)
• Hallandale Pharmacy: $150 to $300
• Olympia Pharmaceuticals: $175 to $399
• Telehealth-bundled platforms (medication + provider): $199 to $599

Price alone is insufficient for comparison. Key differentiators include batch-testing transparency, accreditation status, formulation options (subcutaneous injection vs. sublingual troche vs. oral capsule), and whether the pharmacy provides certificates of analysis on request.

Help offers multiple formulation routes, including injectable semaglutide, sublingual tablets, and troches. The clinical evidence supporting compounded sublingual or oral semaglutide formulations is thinner than for subcutaneous injection. The STEP trial program, which established semaglutide's efficacy for weight management, used subcutaneous injection exclusively. STEP-1 (N=1,961) demonstrated 14.9% mean body weight reduction at 68 weeks with semaglutide 2.4 mg subcutaneous vs. 2.4% with placebo (Wilding et al., NEJM 2021) [11]. Rybelsus (oral semaglutide) uses a proprietary SNAC absorption enhancer that compounded oral formulations do not replicate.

Patients choosing a non-injectable route from any compounder should discuss expected bioavailability differences with their prescribing clinician.

Hidden Costs and Cost Traps to Watch

Three cost traps appear repeatedly in patient forums and reviews of compounded GLP-1 programs that use Help or similar pharmacies.

Dose-escalation surprises. Many platforms advertise starting-dose pricing prominently. A $149/month headline often reflects the 0.25 mg initiation dose. At maintenance (1.0 to 2.4 mg for semaglutide), the same platform may charge $299 to $449. Read the full dose-tier pricing schedule before committing.

Auto-refill and cancellation friction. Some telehealth partners auto-enroll patients in monthly subscriptions with 7- to 14-day cancellation windows. Review terms before providing payment information.

Compounding availability shifts. The FDA's drug shortage list is dynamic. If semaglutide or tirzepatide is removed from the shortage list, 503B compounding of those molecules may face legal challenge. The FDA issued updated guidance in 2024 on compounding of drugs removed from shortage, indicating that pharmacies would have a transition period but could not continue compounding indefinitely [12]. Patients relying on compounded GLP-1 medications should have a contingency plan discussed with their provider.

A 2024 JAMA Internal Medicine viewpoint estimated that if GLP-1 agonists were priced at manufacturing cost plus reasonable margin, a month's supply of semaglutide could cost as little as $40 to $100 (Hernandez et al., JAMA Intern Med 2024) [13]. The gap between that estimate and current compounded pricing reflects pharmacy overhead, quality testing, and platform margins.

What Does Help Pharmacy Prescribe?

Help does not prescribe. It fills prescriptions written by licensed providers. Its compounding catalog spans several therapeutic categories relevant to HealthRX.com readers:

GLP-1 receptor agonists: compounded semaglutide (injectable, sublingual), compounded tirzepatide (injectable). These require a prescription and are typically used for weight management or type 2 diabetes under clinical supervision per ADA Standards of Care [14].

Peptide therapy: BPC-157, thymosin beta-4, PT-141 (bremelanotide), and others. The regulatory status of some peptides has shifted. The FDA's updated category list removed several peptides from the bulk drug substances list in 2023 and 2024, making their compounding status uncertain [15].

Hormone replacement therapy: testosterone cypionate (injectable and topical), estradiol, progesterone, DHEA, and pregnenolone. The Endocrine Society's guideline on testosterone therapy for men with hypogonadism recommends target trough levels of 400 to 600 ng/dL, achievable with compounded testosterone cypionate at doses similar to brand formulations (Bhasin et al., JCEM 2018) [16].

Erectile dysfunction medications: compounded tadalafil, sildenafil, and combination formulations, often at prices well below brand Cialis ($400+/month) or Viagra.

Insurance, HSA, and FSA Considerations

Compounded medications from 503B pharmacies are almost never covered by commercial insurance or Medicare Part D. Patients pay cash (credit card, debit, or ACH transfer). The pricing transparency of cash-pay compounding is, paradoxically, one of its advantages: no prior authorizations, no step therapy requirements, no formulary restrictions.

However, compounded medications purchased with a valid prescription may be eligible for reimbursement through Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA) under IRS rules. The IRS defines qualified medical expenses as those for the "diagnosis, cure, mitigation, treatment, or prevention of disease" (IRS Publication 502) [17]. Patients should save receipts and consult their plan administrator, since some HSA/FSA administrators require a letter of medical necessity for compounded drugs.

For commercially insured patients, the calculus changes. Manufacturer savings programs for brand Wegovy can reduce out-of-pocket costs to $0 to $25/month for eligible patients. Novo Nordisk's savings card covers up to 13 fills [3]. Patients with commercial insurance should price both pathways (brand with savings card vs. compounded cash-pay) before defaulting to compounding.

How to Evaluate Any Compounding Pharmacy

Whether choosing Help or a competitor, apply these five checks:

1. FDA registration status. Confirm the pharmacy appears in the FDA's registered outsourcing facility list.
2. Inspection history. Review the most recent FDA 483 observations. Minor documentation findings are common; repeated sterility failures are not.
3. Accreditation. PCAB accreditation or equivalent third-party quality certification.
4. Certificates of analysis. Legitimate 503B pharmacies should provide potency and sterility test results for any compounded batch on request.
5. Adverse event reporting. Ask whether the pharmacy reports adverse events to FDA MedWatch, as required for 503B facilities under 21 CFR Part 310.305.

"Patients should ask their compounding pharmacy for a certificate of analysis for their specific batch," according to the American Pharmacists Association's 2023 guidance on compounded medication safety [18].